182 related articles for article (PubMed ID: 34308518)
1. A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
Collins JM; Nordstrom BL; McLaurin KK; Dalvi TB; McCutcheon SC; Bennett JC; Murphy BR; Singhal PK; McCrea C; Shinde R; Briceno JM
Oncol Ther; 2021 Dec; 9(2):575-589. PubMed ID: 34308518
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.
Frenel JS; Lusque A; Delaloge S; Ferrero JM; Bachelot T; Desmoulins I; Levy C; Eymard JC; Gonçalves A; Patsouris A; Reynier MAM; Thery MJ; Petit T; Cabel L; Uwer L; Debled M; Chevrot M; Mailliez A; Jacot W; de La Motte Rouge T
Br J Cancer; 2023 Jun; 128(11):2072-2080. PubMed ID: 37012318
[TBL] [Abstract][Full Text] [Related]
4. Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA Status.
Hage AM; Gebert P; Blohmer JU; Hedayati E; Speiser D; Karsten MM
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398129
[TBL] [Abstract][Full Text] [Related]
5. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
Miller RS; Mokiou S; Taylor A; Sun P; Baria K
Breast Cancer Res Treat; 2022 May; 193(1):83-94. PubMed ID: 35194731
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Mailliez A; D'Hondt V; Lusque A; Caron O; Cabel L; Goncalves A; Debled M; Gladieff L; Ferrero JM; Petit T; Mouret-Reynier MA; Eymard JC; Levy C; Uwer L; Leheurteur M; Desmoulins I; Bachelot T; Frenel JS; de la Motte Rouge T; Simon G; Jacot W; Delaloge S
Int J Cancer; 2023 Mar; 152(5):921-931. PubMed ID: 36161271
[TBL] [Abstract][Full Text] [Related]
7. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J; Fasching PA; Couch FJ; Delaloge S; Labidi-Galy I; O'Shaughnessy J; Park YH; Eisen AF; You B; Bourgeois H; Gonçalves A; Kemp Z; Swampillai A; Jankowski T; Sohn JH; Poddubskaya E; Mukhametshina G; Aksoy S; Timcheva CV; Park-Simon TW; Antón-Torres A; John E; Baria K; Gibson I; Gelmon KA;
Breast Cancer Res Treat; 2024 Apr; 204(2):237-248. PubMed ID: 38112922
[TBL] [Abstract][Full Text] [Related]
8. Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status.
Logue CA; Pugh J; Foden P; Mahmood RD; Morgan RD; Mitchell C; Hasan J; Clamp AR; Jayson GC
Sex Med; 2022 Feb; 10(1):100465. PubMed ID: 34922303
[TBL] [Abstract][Full Text] [Related]
9. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
[TBL] [Abstract][Full Text] [Related]
10. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
Alvarez A; Bernal AM; Anampa J
Breast Cancer Res Treat; 2023 Feb; 198(1):75-88. PubMed ID: 36562909
[TBL] [Abstract][Full Text] [Related]
11. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.
Savill KMZ; Ivanova J; Asgarisabet P; Falkenstein A; Balanean A; Niyazov A; Ryan JC; Kish J; Gajra A; Mahtani RL
Oncologist; 2023 May; 28(5):414-424. PubMed ID: 36952230
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing.
Paiella S; Azzolina D; Gregori D; Malleo G; Golan T; Simeone DM; Davis MB; Vacca PG; Crovetto A; Bassi C; Salvia R; Biankin AV; Casolino R
ESMO Open; 2023 Apr; 8(2):100881. PubMed ID: 36822114
[TBL] [Abstract][Full Text] [Related]
13. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
14. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.
Pla H; Felip E; Obadia V; Pernas S; Viñas G; Margelí M; Fort-Culillas R; Del Barco S; Sabaté N; Fort E; Lezcano C; Cirauqui B; Quiroga V; Stradella A; Gil Gil M; Esteve A; Recalde S
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38519708
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Wu EQ
Exp Hematol Oncol; 2015; 4():31. PubMed ID: 26693096
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
19. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes.
Bruno L; Ostinelli A; Waisberg F; Enrico D; Ponce C; Rivero S; Blanco A; Zarba M; Loza M; Fabiano V; Amat M; Pombo MT; Noro L; Chacón M; Coló F; Chacón R; Nadal J; Nervo A; Costanzo V
JCO Precis Oncol; 2022 Mar; 6():e2100140. PubMed ID: 35235412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]